Trials / Completed
CompletedNCT05521139
Risk Factors for Pyogenic Liver Abscess With Carbapenem-resistant Klebsiella Pneumoniae: A Matched Case-control Study
A Matched Case-control Study of Carbapenem Resistant and Carbapenem Sensitive Klebsiella Pneumoniae Infected Pyogenic Liver Abscess
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 15 (actual)
- Sponsor
- Xiangya Hospital of Central South University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Pyogenic liver abscess (PLA) is a complication of infectious disease, and the most common pathogen of PLA is Klebsiella pneumoniae, while PLA caused by Carbapenem-resistant Klebsiella pneumoniae (CRKP) has become a threat to public health. For achieving a better therapeutic outcome of CRKP related PLA, it is very important to figure out the basic characteristics and risk factors of CRKP-PLA. A retrospective cohort study was performed in which 15 PLA patients carriage of K pneumoniae were screened at the Xiangya hospital of central south university (changsha, China). The colonization and clinical infection isolates were analyzed by antimicrobial susceptibility testing to identify CRKP. All admission patients diagnosed with PLA who developed CRKP were included, 5 adults PLA patients with CRKP infected and 10 adults PLA patients with Carbapenem sensitive Klebsiella pneumoniae (CSKP) infected were conducted. Univariate and multivariate logistic regression was carried out using a stepwise selection method to compare prognostic factors between CRKP and CSKP groups.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | drug sensitivity results | drug sensitivity results including the carbapenem-resistant Klebsiella pneumoniae and carbapenem-sensitive Klebsiella pneumoniae |
Timeline
- Start date
- 2020-04-01
- Primary completion
- 2020-06-30
- Completion
- 2020-06-30
- First posted
- 2022-08-30
- Last updated
- 2022-08-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05521139. Inclusion in this directory is not an endorsement.